Sort
4,870 grants matching “glp 1”
Toward optimizing diabetes care in persons with chronic kidney disease
$154,040Jinnie J. Rhee · Stanford University · K01 · FY2020 · DK
Toward optimizing diabetes care in persons with chronic kidney disease
$154,040Jinnie J. Rhee · Stanford University · K01 · FY2019 · DK
Life Course Obesity Research Informatics Core
$153,892Joyce Lee · University Of Michigan At Ann Arbor · P30 · FY2025 · DK
Examining the role of locus coeruleus glucagon-like peptide-1 receptors in feeding behavior
$153,846Samantha Fortin · University Of Pennsylvania · K01 · FY2024 · DK
Examining the role of locus coeruleus glucagon-like peptide-1 receptors in feeding behavior
$153,846Samantha Fortin · University Of Pennsylvania · K01 · FY2025 · DK
A Novel Class of Lipids as Potential Therapeutic Agents to Promote Pancreatic Beta cell Survival and Prevent Type 1 Diabetes.
$153,749Ismail Syed · Beth Israel Deaconess Medical Center · K01 · FY2019 · DK
A Novel Class of Lipids as Potential Therapeutic Agents to Promote Pancreatic Beta cell Survival and Prevent Type 1 Diabetes.
$153,749Ismail Syed · Beth Israel Deaconess Medical Center · K01 · FY2020 · DK
Core D: PREVENT Program Regulatory Affairs Core
$153,669Ian Michael McGowan · University Of Louisville · U19 · FY2014 · AI
CLINICAL PROJECT: The Role of Phosphodiesterase Inhibitors in Incretin Secretion
$153,569Chee W Chia · National Institute On Aging · ZIA · FY2025 · AG
CLINICAL TRIAL: EFFECTS OF PIOGLITAZONE ON INCRETIN AXIS IN PTS W TYPE 2 DIABETE
$153,191Richard E Pratley · University Of Vermont & St Agric College · M01 · FY2010 · RR
PTPRD Phosphatase inhibitors for stimulant use disorders
$153,168George R Uhl · University Of Maryland Baltimore · UG3 · FY2024 · DA
Novel Recombinant Anticoagulant Proteins
$152,652Evas Therapeutics, Llc. · R43 · FY2005 · HL
Effect of dipeptidyl peptidase 4 inhibition on growth hormone secretion
$152,415Jessica K Devin · Vanderbilt University · K23 · FY2014 · HL
Effect of dipeptidyl peptidase 4 inhibition on growth hormone secretion
$152,415Jessica K Devin · Vanderbilt University · K23 · FY2015 · HL
Restoration of Skin Structure and Function Post-Wounding
$152,255Robert G Gourdie · Xequel Bio, Inc. · R41 · FY2006 · AR
Clinical Development of a Safety and Efficacy-Optimized 2nd Generation HCMV/HIV Vector for a Prophylactic HIV/AIDS Vaccine
$152,018Thomas G Evans · Oregon Health & Science University · U19 · FY2017 · AI
Glucagon-Like Peptide-1 (GLP-1) Signaling in the Olfactory System
$152,000Nicolas Thiebaud · Florida State University · R03 · FY2017 · DC
Glucagon-Like Peptide-1 (GLP-1) Signaling in the Olfactory System
$152,000Nicolas Thiebaud · Florida State University · R03 · FY2018 · DC
Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events
$151,903James Blackledge · Capella Imaging, Llc · R42 · FY2017 · HL
Role of the bile acid activated receptors FXR and TGR5 in Total Parenteral Nutrition associated hepatic and gut disease
$151,632Ajay K. Jain · Saint Louis University · K08 · FY2019 · DK
Role of the bile acid activated receptors FXR and TGR5 in Total Parenteral Nutrition associated hepatic and gut disease
$151,632Ajay K. Jain · Saint Louis University · K08 · FY2018 · DK
Role of the bile acid activated receptors FXR and TGR5 in Total Parenteral Nutrition associated hepatic and gut disease
$151,632Ajay K. Jain · Saint Louis University · K08 · FY2017 · DK
Role of the bile acid activated receptors FXR and TGR5 in Total Parenteral Nutrition associated hepatic and gut disease
$151,632Ajay K. Jain · Saint Louis University · K08 · FY2020 · DK
Pre-Clinical Vector Production Core
$151,030William F. Goins · Brigham And Women'S Hospital · P01 · FY2020 · CA
The Comparative Effectiveness and Safety of Second-line Therapy in Patients with Type 2 Diabetes
$150,982Jung-Im Shin · Johns Hopkins University · K01 · FY2022 · DK